Central Asia vs Iran (Islamic Republic of): Proportion of the target population … measles-containing-vaccine
Central Asia
97.0%
in 2024
Iran (Islamic Republic of)
99.0%
in 2024
Central Asia rank
1st
Iran (Islamic Republic of) rank
1st
Proportion of the target population … measles-containing-vaccine over time
- Central Asia
- Iran (Islamic Republic of)
How they compare
Iran (Islamic Republic of) currently reports 99.0% against 97.0% in Central Asia, a difference of 2.0%.
The two have swapped places 6 times across 25 shared years of data; in 2000 it was Iran (Islamic Republic of) ahead.
Central Asia ranks 1st and Iran (Islamic Republic of) ranks 1st of 36 groups.
Iran (Islamic Republic of) has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Central Asia | Iran (Islamic Republic of) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 84.3% | 96.6% | 12.3% | Iran (Islamic Republic of) |
| 2010s | 96.5% | 98.0% | 1.5% | Iran (Islamic Republic of) |
| 2020s | 97.4% | 98.4% | 1.0% | Iran (Islamic Republic of) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received, Central Asia or Iran (Islamic Republic of)?
- Iran (Islamic Republic of), at 99.0% against 97.0% in Central Asia as of 2024.
- What is the difference in proportion of the target population who received between Central Asia and Iran (Islamic Republic of)?
- 2.0%, with Iran (Islamic Republic of) ahead.
- How many years of comparable data are there for Central Asia and Iran (Islamic Republic of)?
- 25 years are reported by both, from 2000 to 2024.
- How do Central Asia and Iran (Islamic Republic of) rank globally for proportion of the target population who received?
- Central Asia ranks 1st and Iran (Islamic Republic of) ranks 1st of 36 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received measles-containing-vaccine second-dose (MCV2) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.